Tina Fox
Psychiatric/Mental Health · Chattanooga, TNNPI 1760632434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 750 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 750 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Corium, LLC$1K
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$991
- plus $6K from 23 others
What the payments were for
- Food & beverage$14,284100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 94 | $1,997 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $1,395 |
| Otsuka America Pharmaceutical, Inc. | 106 | $1,188 |
| Corium, LLC | 53 | $1,181 |
| Supernus Pharmaceuticals, Inc. | 43 | $1,148 |
| AbbVie | 53 | $991 |
| Alkermes, Inc. | 41 | $972 |
| Teva Pharmaceuticals USA, Inc. | 42 | $821 |
| Johnson & Johnson | 40 | $700 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $553 |
| Vanda Pharmaceuticals Inc. | 20 | $522 |
| Lundbeck LLC | 21 | $436 |
| Almatica Pharma LLC | 27 | $427 |
| Axsome Therapeutics, Inc. | 18 | $405 |
| Eisai Inc. | 12 | $281 |
| Ironshore Pharmaceuticals Inc. | 13 | $226 |
| Sunovion Pharmaceuticals Inc. | 11 | $189 |
| E.r. Squibb & Sons, L.L.C. | 7 | $160 |
| Collegium Pharmaceutical, Inc. | 10 | $139 |
| Avanir Pharmaceuticals, Inc. | 4 | $105 |
| Tris Pharma Inc | 5 | $93 |
| Merck | 5 | $81 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Jazz Pharmaceuticals Inc. | 4 | $72 |
| Noven Therapeutics, LLC | 2 | $49 |
| Neos Therapeutics, LP | 2 | $40 |
| Bausch Health US, LLC | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Alfasigma USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,331 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $177,188 |
| Austedo XrDeutetrabenazine | 14 | $146,356 |
| RexultiBrexpiprazole | 24 | $38,798 |
| VraylarCariprazine Hcl | 26 | $35,388 |
| CaplytaLumateperone Tosylate | 20 | $31,574 |
| Lurasidone Hcl | 64 | $20,435 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 137 | $11,804 |
| Bupropion XlBupropion Hcl | 287 | $9,701 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 251 | $8,579 |
| Aripiprazole | 214 | $8,481 |
| Duloxetine Hcl | 207 | $5,261 |
| Buspirone Hcl | 204 | $4,995 |
| Lamotrigine | 293 | $4,628 |
| DayvigoLemborexant | 14 | $4,447 |
| Quetiapine Fumarate | 266 | $4,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,997 | $177,18821 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $821 | $146,35614 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,188 | $38,79824 claims |
| AbbVieVraylar | $991 | $35,38826 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,395 | $31,57420 claims |
| Eisai Inc.Dayvigo | $281 | $4,44714 claims |
| Almatica Pharma LLCSertraline Hcl | $427 | $1,508238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Chattanooga
- Joshua ThompsonChattanooga$262K
- Jason HamrickChattanooga$17K
- Trena LawsonChattanooga$13K
- Erin LawsonChattanooga$10K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Kristal HurstBlaine$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.